REGLAN LINKED TO TARDIVE DYSKINESIA
Reglan (metoclopramide), a prescription medication used to treat gastroesophageal reflux (GER) and gastroesophageal reflux disease (GERD) in children and adults has been linked with Tardive Dyskinesia, a potentially permanent movement disorder.
Tardive Dyskinesia is a neurological disorder that consists of potentially irreversible, involuntary movements of the tongue, mouth, face, lips, and sometimes the arms, legs, and trunk. Both the risk of developing the syndrome and the likelihood that it will become irreversible are believed to increase with the duration of Reglan use and the total cumulative dose.
The FDA approved Reglan in 1995 for short-term use, generally 4 to 12 weeks. However, one-third of patients taking Reglan and the generic form, metoclopramide, are doing so for periods of 12 months or longer. Of these long-term users, there is a prevalence of Tardive Dyskinesia in 27 percent to 29 percent of these patients.
In a study published in the Journal of the American Pharmacists Association in 2004, experts from the Duke University School of Medicine caution that the use of Reglan is on the rise. As a result, more cases of drug-induced Tardive Dyskinesia may develop.
Tardive Dyskinesia is characterized by repetitive, involuntary movements. These symptoms range from being very mild to very severe, which may be irreversible. Some of these symptoms include:
- Jerking movements of the tongue, face, mouth, and jaw
- Involuntary movement of the hands and fingers
- Uncontrolled movement of the arms, legs, and trunk
- Uncontrolled facial grimacing
- Tongue protrusion
- Lip smacking
- Rapid eye blinking
If you or a loved one has developed Tardive Dyskinesia as a result of taking Reglan, see your doctor immediately for an evaluation.